Impact of tumor hypoxia and anemia on radiation therapy outcomes.

  title={Impact of tumor hypoxia and anemia on radiation therapy outcomes.},
  author={Louis B. Harrison and Manjeet Chadha and Richard Hill and Kenneth Shung Hu and Daniel Shasha},
  journal={The oncologist},
  volume={7 6},
Local recurrence remains a major obstacle to achieving cure of many locally advanced solid tumors treated with definitive radiation therapy. The microenvironment of solid tumors is hypoxic compared with normal tissue, and this hypoxia is associated with decreased radiosensitivity. Recent preclinical data also suggest that intratumoral hypoxia, particularly in conjunction with an acid microenvironment, may be directly or indirectly mutagenic. Investigations of the prognostic significance of the… 

Tables from this paper

Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?

Early evidence from experimental and clinical studies suggests the administration of recombinant human erythropoietin (rHuEPO) may enhance the effectiveness of radiation therapy and chemotherapy by increasing hemoglobin levels and ameliorating anemia in patients with disease- or treatment-related anemia.

Targeting Tumor Hypoxia

Tumor hypoxia significantly impacts tumor radiosensitivity and subsequently leads to poor clinical outcomes in patients treated with radiation therapy, and the lack of robust, widely available, and adequately validated biomarkers for assessing tumor Hypoxia in patients is a major limitation.

rHuEPO and treatment outcomes: the preclinical experience.

It is suggested that correction of anemia by rHuEPO can increase tumor sensitivity to both radiation therapy and chemotherapy and that epoetin alfa may exert an immunomodulatory effect in multiple myeloma.

The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities.

The assessment of tumor Hypoxia will be valuable to radiation oncologists, surgeons, and biotechnology and pharmaceutical companies who are engaged in developing hypoxia-based therapies or treatment strategies.

Impact of anemia in patients with head and neck cancer treated with radiation therapy

The impact of anemia on outcomes after radiotherapy of head and neck cancers is reviewed and quality-of-life studies suggest that correction of moderately severe anemia may result in significant gains.

Hypoxia Image Guided Radiation Therapy: Current Status and Major Challenges

The article reviews the current status on clinical and preclinical research on HIGRT and major challenges to be addressed in the future development.

Therapeutic targeting of tumor hypoxia and necrosis with antibody α-radioconjugates

This work will review current literature examining radioconjugate therapy specifically targeting necrotic and hypoxic tumor cells and outline how α-radioconjugates could be used to treat tumor regions harboring more resistant cancer cell types.

Expression of hypoxia-inducible factor 1α predicts clinical outcome after preoperative hyperthermo-chemoradiotherapy for locally advanced rectal cancer.

Evaluating the predictive value of tumor response to preoperative hyperthermo-chemoradiotherapy (HCRT) and the prognostic significance of HIF-1α expression in patients with locally advanced rectal cancer found it might be predictive of recurrence- free survival and metastasis-free survival rate forrectal cancer patients treated with HCRT.

Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer

It is identified that a subtherapeutic dose of trastuzumab sensitizes the tumor microenvironment to fractionated radiation, which results in longitudinal sustained response by triggering a state of innate immune activation through reduced DNA damage repair and increased tumor oxygenation.



Prevalence of Anemia in Cancer Patients Undergoing Radiotherapy: Prognostic Significance and Treatment

Radiation oncologists need to be aware of the possibility of anemia in cancer patients undergoing radiotherapy so that timely intervention can be instituted whenever anemia is diagnosed.

Imaging hypoxia in tumors.

  • J. Ballinger
  • Medicine, Biology
    Seminars in nuclear medicine
  • 2001
Noninvasive imaging with a hypoxia-directed radiopharmaceutical could be of great clinical utility, and 1-123-IAZA and Cu-60-ATSM have shown correlation with response to radiotherapy in preliminary clinical studies.

Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix.

  • M. HöckelC. Knoop P. Vaupel
  • Medicine
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 1993

Influence of the hypoxic subvolume on the survival of patients with head and neck cancer.

The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience.

It seems that patients reacting sufficiently to rhEPO stimulation can expect better locoregional tumor control within the irradiation volume, and this, however, awaits confirmation in an ongoing trial.

The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture.

  • J. Brown
  • Biology, Medicine
    Cancer research
  • 1999
The recent development of new drugs that are nontoxic until they are activated in the hypoxic cell opens a new era of selective cancer therapy.

Oxygenation predicts radiation response and survival in patients with cervix cancer.

  • A. FylesM. Milosevic R. Hill
  • Medicine
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 1998

Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck.

Sensitization of hypoxic tumour cells--clinical experience.

  • J. Overgaard
  • Medicine
    International journal of radiation biology
  • 1989
A definitive solution to the hypoxia problem will not be found until the tumours in which Hypoxia occurs can be identified, and this will require detailed analysis of individual tumours and patients' parameters, and better knowledge of the mechanisms of reoxygenation in clonogenic tumour cells.